Enhancing chemotherapeutic responses in CNS malignancy through suppression of hyperactive DNA damage repair pathways
MetadataShow full item record
Current methods to treat medulloblastoma (MB) and malignant glioma (MG) are highly intrusive with three-year survival. Recurrence is high due to chemoradio-resistance. We are targeting DNA repair pathways through inhibitors of DNA repair proteins; Poly (ADP-Ribose) Polymerase (PARP1i), DNA-dependent protein kinase (DNA-PKi) and Ataxia-Telangiectasia Mutated (ATMi) to sensitize tumours to DNA damaging agents. However, differing tumours have variable expression of these enzymes/repair pathway(s) activity, therefore; their identification and inhibition may enhance current treatment efficacy. High-throughput comet assay revealed enhanced drug-mediated tumour cell death in MB cell lines with TOPI+PARP1i with activation of specific repair pathways. Further, RNA-Seq analysis revealed PARP1 upregulated in DAOYMB and downregulated in D283; while BRCA1 downregulated in DAOYMB and upregulated in D283MB, suggesting defective Homologous recombination (HRR) pathway, hence synthetic lethality in MB cell line (DAOYMB). Therefore, I have identified unique DNA repair enzymes, which may mediate specific differential chemo-radioresistant phenotypes in MB.
- FGS - Electronic Theses and Practica 
- Manitoba Heritage Theses